Simplex Trading’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $474K | Sell |
43,500
-37,100
| -46% | -$463K | ﹤0.01% | 3326 |
|
|
2025
Q4 | $1.04M | Sell |
80,600
-27,300
| -25% | -$350K | ﹤0.01% | 2588 |
|
|
2025
Q3 | $1.39M | Buy |
107,900
+27,600
| +34% | +$369K | ﹤0.01% | 2703 |
|
|
2025
Q2 | $1.43M | Buy |
80,300
+21,900
| +38% | +$382K | ﹤0.01% | 2423 |
|
|
2025
Q1 | $1.04M | Sell |
58,400
-35,600
| -38% | -$809K | ﹤0.01% | 2671 |
|
|
2024
Q4 | $2.8M | Buy |
94,000
+14,900
| +19% | +$315K | ﹤0.01% | 1913 |
|
|
2024
Q3 | $1.24M | Buy |
79,100
+28,600
| +57% | +$519K | ﹤0.01% | 2712 |
|
|
2024
Q2 | $865K | Sell |
50,500
-80,700
| -62% | -$1.42M | ﹤0.01% | 3070 |
|
|
2024
Q1 | $2.05M | Buy |
131,200
+99,300
| +311% | +$1.46M | ﹤0.01% | 2390 |
|
|
2023
Q4 | $476K | Sell |
31,900
-12,700
| -28% | -$170K | ﹤0.01% | 3754 |
|
|
2023
Q3 | $720K | Sell |
44,600
-103,500
| -70% | -$2.98M | ﹤0.01% | 3014 |
|
|
2023
Q2 | $6.15M | Buy |
148,100
+31,300
| +27% | +$1.94M | 0.01% | 1182 |
|
|
2023
Q1 | $7.02M | Buy |
116,800
+70,500
| +152% | +$5.63M | 0.01% | 1090 |
|
|
2022
Q4 | $3.4M | Buy |
46,300
+12,900
| +39% | +$971K | ﹤0.01% | 1469 |
|
|
2022
Q3 | $2.54M | Buy |
33,400
+7,100
| +27% | +$554K | ﹤0.01% | 1750 |
|
|
2022
Q2 | $1.83M | Sell |
26,300
-21,300
| -45% | -$1.6M | ﹤0.01% | 1967 |
|
|
2022
Q1 | $3.94M | Buy |
47,600
+11,100
| +30% | +$818K | ﹤0.01% | 1450 |
|
|
2021
Q4 | $2.74M | Buy |
36,500
+19,400
| +113% | +$1.95M | ﹤0.01% | 1723 |
|
|
2021
Q3 | $3.24M | Buy |
17,100
+100
| +0.6% | +$15.1K | ﹤0.01% | 1594 |
|
|
2021
Q2 | $3.77M | Buy |
17,000
+16,739
| +6,413% | +$3.26M | ﹤0.01% | 1445 |
|
|
2021
Q1 | $3.45M | Sell |
261
-514
| -66% | -$81.3K | 0.01% | 1120 |
|
|
2020
Q4 | $13.4M | Sell |
775
-42
| -5% | -$5.75K | 0.02% | 469 |
|
|
2020
Q3 | $9.09M | Buy |
817
+177
| +28% | +$14.2K | 0.01% | 554 |
|
|
2020
Q2 | $3.79M | Sell |
640
-295
| -32% | -$19.4K | 0.01% | 1032 |
|
|
2020
Q1 | $6.3M | Buy |
935
+505
| +117% | +$39.9K | 0.01% | 588 |
|
|
2019
Q4 | $3.62M | Buy |
430
+123
| +40% | +$9.93K | 0.01% | 1009 |
|
|
2019
Q3 | $2.29M | Sell |
307
-81
| -21% | -$6.48K | 0.01% | 1230 |
|
|
2019
Q2 | $2.45M | Buy |
388
+31
| +9% | +$1.57K | 0.01% | 1162 |
|
|
2019
Q1 | $1.72M | Buy |
357
+261
| +272% | +$12.6K | ﹤0.01% | 1512 |
|
|
2018
Q4 | $321K | Sell |
96
-125
| -57% | -$4.57K | ﹤0.01% | 2648 |
|
|
2018
Q3 | $1.16M | Buy |
221
+188
| +570% | +$7.48K | ﹤0.01% | 1745 |
|
|
2018
Q2 | $103K | Sell |
33
-1,098
| -97% | -$30.5K | ﹤0.01% | 4255 |
|
|
2018
Q1 | $62K | Buy |
1,131
+894
| +377% | +$19.2K | ﹤0.01% | 2219 |
|
|
2017
Q4 | $47K | Buy |
237
+135
| +132% | +$2.6K | ﹤0.01% | 2508 |
|
|
2017
Q3 | $53K | Buy |
102
+59
| +137% | +$1.16K | ﹤0.01% | 2251 |
|
|
2017
Q2 | $7K | Sell |
43
-136
| -76% | -$1.76K | ﹤0.01% | 4310 |
|
|
2017
Q1 | $14K | Sell |
179
-73
| -29% | -$527 | ﹤0.01% | 3646 |
|
|
2016
Q4 | $3K | Sell |
252
-191
| -43% | -$1.54K | ﹤0.01% | 4774 |
|
|
2016
Q3 | $38K | Buy |
443
+293
| +195% | +$2.67K | ﹤0.01% | 2354 |
|
|
2016
Q2 | $8K | Buy |
150
+79
| +111% | +$989 | ﹤0.01% | 3811 |
|
|
2016
Q1 | $13K | Sell |
71
-64
| -47% | -$918 | ﹤0.01% | 3223 |
|
|
2015
Q4 | $11K | Buy |
+135
| New | +$3.23K | ﹤0.01% | 3215 |
|
Other funds holding NVCR
SCM
VPM
VCM
QCM
Simplex Trading's NVCR Position: Q1 2026 in Review
Simplex Trading increased its NovoCure (NVCR) stake by 115% in Q1 2026, buying an estimated $90.7K and bringing the position to 13,561 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #4649.
Simplex Trading first reported a position in NVCR in Q2 2016 and has held it in 30 quarters since. The position peaked at $2.38M in Q2 2021. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.
- Simplex Trading held 13,561 shares of NovoCure worth $148K as of Q1 2026.
- Simplex Trading bought 7,260 NovoCure shares in Q1 2026, an estimated $90.7K.
- NovoCure made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #4649 holding.
- Simplex Trading first reported a position in NovoCure in Q2 2016 and has held it in 30 quarters since.
- Simplex Trading's NovoCure position peaked at $2.38M in Q2 2021.
- 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.
Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.